en.as.com
Cure8 news brief
Why This Matters
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because insurance coverage or pharmacy supply could change.
Who Should Pay Attention
Adult patients with Crohn’s disease or ulcerative colitis who use biologic therapies, clinicians who prescribe these drugs, pharmacists, and patients interested in medication costs or biosimilars.
Study Snapshot
Story typeMainstream News
Evidence typePatient Education
Source depthFull source text
What To Know
Patent expirations mean manufacturers can face generic or biosimilar competition. For IBD patients, that often leads to new biosimilars entering the market for biologic therapies such as ustekinumab (Stelara), golimumab (Simponi), and natalizumab (Tysabri).
These market changes can influence drug pricing, insurance coverage, and treatment options but do not directly change how these drugs are used clinically.
If you are on any of the drugs mentioned, talk with your care team or pharmacist before making any changes; switching to a biosimilar is a clinical decision involving efficacy, safety, and insurance considerations.
Keep an eye on insurer communications and FDA/biosimilar approvals over the coming months, since product launches and coverage decisions follow patent expirations.
Keep In Mind
This is a news roundup about patent expirations compiled from industry reporting. Patent loss is a market/legal event; biosimilar availability, FDA approvals, pricing, and payer policies determine real-world access and timing. This article does not report new clinical trial results or guidance about switching therapies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationen.as.com
Indexed viaBing News
Source typeMainstream News
PublishedApr 10, 2025, 5:14 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...